The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Subscribe To Our Newsletter & Stay Updated
